NASDAQ:FNCH Finch Therapeutics Group (FNCH) Stock Price, News & Analysis $12.70 -0.04 (-0.31%) As of 08/15/2025 12:40 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Finch Therapeutics Group Stock (NASDAQ:FNCH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FNCH alerts:Sign Up Key Stats Today's Range$12.68▼$12.7050-Day Range$12.03▼$13.7552-Week Range$10.15▼$15.85Volume3,026 shsAverage Volume2,030 shsMarket Capitalization$20.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. Read More Receive FNCH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address FNCH Stock News HeadlinesFNCH - Finch Therapeutics Group Inc Price vs Fair Value - MorningstarJuly 4, 2025 | morningstar.comMFNCH Finch Therapeutics Group, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just discovered a new way to do it with 10X less money.August 18 at 2:00 AM | Investors Alley (Ad)Arquitos Capital's Largest Holdings For Q1 2025May 1, 2025 | seekingalpha.comArquitos Capital Management Q4 2024 CommentaryFebruary 5, 2025 | seekingalpha.comFinch Therapeutics Group, Inc.: Finch Announces Delisting from Nasdaq and SEC DeregistrationOctober 23, 2024 | finanznachrichten.deFinch Therapeutics announces Nasdaq delisting, SEC deregistrationOctober 22, 2024 | markets.businessinsider.comFinch Therapeutics Group to Delist from NasdaqOctober 22, 2024 | markets.businessinsider.comSee More Headlines FNCH Stock Analysis - Frequently Asked Questions How have FNCH shares performed this year? Finch Therapeutics Group's stock was trading at $11.30 on January 1st, 2025. Since then, FNCH stock has increased by 12.4% and is now trading at $12.70. How were Finch Therapeutics Group's earnings last quarter? Finch Therapeutics Group, Inc. (NASDAQ:FNCH) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($6.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($12.60) by $6.30. The business earned $11.34 million during the quarter. When did Finch Therapeutics Group's stock split? Finch Therapeutics Group's stock reverse split on Monday, June 12th 2023.The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Finch Therapeutics Group IPO? Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Finch Therapeutics Group? Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Finch Therapeutics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO). Company Calendar Last Earnings11/10/2021Today8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FNCH CIK1733257 Webwww.finchtherapeutics.com Phone617-229-6499FaxN/AEmployees190Year FoundedN/AProfitability EPS (Trailing Twelve Months)($8.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.75 million Net MarginsN/A Pretax MarginN/A Return on Equity-69.14% Return on Assets-26.92% Debt Debt-to-Equity RatioN/A Current Ratio3.87 Quick Ratio3.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.25 per share Price / Book0.89Miscellaneous Outstanding Shares1,606,000Free Float885,000Market Cap$20.40 million OptionableNo Data Beta1.19 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:FNCH) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.